First approved in 2012, roll out of oral PrEP has been slow, uneven, and marked by troubling and unacceptable uptake disparities across race/ethnicity, gender and geography. The recently updated National HIV/AIDS Strategy for 2022-2025 recognizes the need for much greater use of PrEP. In 2019, less than 25% of people eligible for PrEP in the U.S. received a prescription. Late last year, the U.S. FDA approved a new PrEP agent called Apretude, an injectable, longer-acting PrEP option. While hopes are high for this intervention, it is replete with challenges from both the user as well as the delivery sides of the equation.
- What have we learned over the past decade that will help us not only do better with injectable PrEP, but improve oral implementation as well?
- How can programs and products reach communities most vulnerable to HIV and ensure equity in access?
- What new ideas are out there to reduce friction in our systems and structures?
- How do we best expand the prevention buffet to enhance choice and autonomy?
Please join AIDS Foundation Chicago, AVAC, and our stellar array of speakers for presentations and debate on what must happen to ensure swift translation of positive research results into community impact. The webinar will be co-moderated by Mitchell Warren of AVAC and Jim Pickett, consultant. Singer and spoken word artist Storie Deveraux will be featured throughout the program. Gratitude to Merck for their unrestricted funding in support of this program.
- Sean E. Bland, O’Neill Institute for National and Global Health Law
- Raniyah M. Copeland, Health, Racial, and Gender Equity Advocate
- Dr. Demetre Daskalakis, CDC Director of the Division of HIV/AIDS Prevention
- Dr. Aniruddha (Anu) Hazra, University of Chicago Medicine & Howard Brown Health
- Amy Killelea, JD, Consultant
- Storie Deveraux – singer and spoken word artist
- Mitchell Warren, AVAC
- Jim Pickett, consultant
Register here: https://tinyurl.com/areweprepared